Skip to main content
. 2023 Jun 5;6(6):e2316642. doi: 10.1001/jamanetworkopen.2023.16642

Table 1. Patient Characteristics.

Characteristic Overall cohort (N = 24 620)a Prepandemic (n = 20 495) Pandemic (n = 14 248)
Age at initial diagnosis, yb
Median (IQR) 68 (60-75) 69 (60-76) 68 (59-75)
≤49 1940 (8) 1639 (8) 1213 (9)
50-64 7005 (28) 5909 (29) 4270 (30)
65-74 8268 (34) 6892 (24) 4852 (34)
≥75 7407 (30) 6055 (30) 3913 (28)
Sex
Women 10 248 (42) 8495 (41) 5966 (42)
Men 14 370 (58) 11 998 (59) 8282 (58)
Unknown <5 (<1) <5 (<1) 0
Race and ethnicity
Hispanic or Latino 1382 (6) 1173 (6) 788 (6)
Non-Hispanic Asian 391 (2) 327 (2) 219 (2)
Non-Hispanic Black or African American 2383 (10) 2002 (10) 1441 (10)
Non-Hispanic White 16 309 (66) 13 769 (67) 9342 (66)
Otherc 2231 (9) 1745 (9) 1331 (9)
Unknown 1924 (8) 1479 (7) 1127 (8)
Disease type
Acute myeloid leukemia 4556 (19) 3719 (18) 1973 (14)
Chronic lymphocytic leukemia 5052 (21) 4191 (20) 3720 (26)
Diffuse large B-cell lymphoma 3861 (16) 3146 (15) 2431 (17)
Follicular lymphoma 2135 (9) 1772 (9) 1234 (9)
Mantle cell lymphoma 1992 (8) 1666 (8) 955 (7)
Multiple myeloma 7024 (29) 6001 (29) 3935 (28)
a

Unless indicated otherwise, values are presented as No. (%) of patients. The N value is the number of unique patients in the cohort or specified period (there is an overlap of patients in the prepandemic and pandemic periods).

b

Some patients had multiple hematologic neoplasms and thus had different ages at initial diagnosis depending on the disease. These patients were counted multiple times for this characteristic, resulting in a total N value for the characteristic that is greater than that for the cohort.

c

Specific race and ethnicity categories with lower representation in the US population were grouped as other for deidentification purposes and may include American Indian or Alaska Native, Hawaiian or Pacific Islander, or multiple races and ethnicities.